Related Experiment Video
Updated: Jul 7, 2026
10:04
Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
Published on: May 1, 2015
Multiple myeloma: novel approaches for relapsed disease
1Winship Cancer Institute, Emory University School of Medicine, 1365 Clifton Road, Atlanta, GA 30322, USA. sloni01@emory.edu
Clinical Lymphoma & Myeloma
|March 8, 2008
Summary
Novel agents like bortezomib and lenalidomide are transforming multiple myeloma (MM) treatment. Combinations with conventional agents, including bendamustine, show promise for newly diagnosed and relapsed MM patients.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- Multiple myeloma (MM) therapeutics are evolving rapidly.
- Novel agents have significantly improved patient outcomes.
- Conventional agents are being re-evaluated in combination therapies.
Purpose of the Study:
- To review emerging data on novel agents and alkylating agents for MM.
- To summarize combination therapies for newly diagnosed and relapsed MM.
- To highlight the role of bendamustine in MM treatment.
Main Methods:
- Literature review of recent clinical studies.
- Analysis of data on novel agents (bortezomib, lenalidomide).
- Evaluation of bendamustine's efficacy as a single agent and in combination.
Main Results:
- Bortezomib and lenalidomide demonstrate high activity in MM.
- Combinations of novel and conventional agents show significant efficacy.
- Bendamustine exhibits activity alone and with novel agents.
Conclusions:
- Novel agents have reshaped MM treatment paradigms.
- Combination therapies offer improved outcomes for MM patients.
- Bendamustine is a promising agent in MM treatment strategies.
Related Concept Videos
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.